Patent watch: Have the biosimilar floodgates been opened in the United States?
Chemical, Biotechnology and Pharmaceutical Practice at Foley &Lardner LLP, 3000 K Street N.W., Suite 600, Washington, DC 20007-5109, USA, and the Editor of Foley &Lardner LLP's PharmaPatentsBlog.com.
Courtenay C
CC
Brinckerhoff
Chemical, Biotechnology and Pharmaceutical Practice at Foley &Lardner LLP, 3000 K Street N.W., Suite 600, Washington, DC 20007-5109, USA.
Kristel
K
Schorr
D059451:Biosimilar Pharmaceuticals; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration
D059451:Biosimilar Pharmaceuticals